NRG Therapeutics Limited
NRG Therapeutics is a neuroscience-focused drug discovery company dedicated to developing disease-modifying treatments for neurodegenerative disorders such as Parkinson’s and ALS. The company leverages breakthrough science in mitochondrial biology to identify new therapeutic targets, focusing on inhibitors of the mitochondrial permeability transition pore (mPTP) that are orally bioavailable and brain-penetrant. Their mission is to slow or halt disease progression and bring hope to patients worldwide.
Industries
Nr. of Employees
small (1-50)
NRG Therapeutics Limited
Cambridge, Cambridgeshire, United Kingdom, Europe
Products
Pipeline of brain-penetrant small-molecule mPTP inhibitors (preclinical)
Structurally differentiated small-molecule series designed to inhibit the mitochondrial permeability transition pore with oral bioavailability and CNS penetration; developed for potential disease-modifying treatment of Parkinson's disease and ALS/MND.
Development candidate: first-in-class brain-penetrant mPTP inhibitor (development candidate)
A nominated preclinical development candidate designed to prevent mitochondrial dysfunction via inhibition of a protein essential for mPTP opening; intended for advancement into first-in-human clinical studies.
Pipeline of brain-penetrant small-molecule mPTP inhibitors (preclinical)
Structurally differentiated small-molecule series designed to inhibit the mitochondrial permeability transition pore with oral bioavailability and CNS penetration; developed for potential disease-modifying treatment of Parkinson's disease and ALS/MND.
Development candidate: first-in-class brain-penetrant mPTP inhibitor (development candidate)
A nominated preclinical development candidate designed to prevent mitochondrial dysfunction via inhibition of a protein essential for mPTP opening; intended for advancement into first-in-human clinical studies.
Services
Integrated lead optimisation services (assay biology, medicinal chemistry, computational chemistry)
Execution of integrated lead optimisation programs through external discovery services partners to improve pharmaceutical properties and progress candidates toward preclinical nomination.
Research collaboration and sponsored academic research management
Sponsorship and management of collaborative research with academic institutes to validate targets, develop biomarkers and perform translational studies.
Integrated lead optimisation services (assay biology, medicinal chemistry, computational chemistry)
Execution of integrated lead optimisation programs through external discovery services partners to improve pharmaceutical properties and progress candidates toward preclinical nomination.
Research collaboration and sponsored academic research management
Sponsorship and management of collaborative research with academic institutes to validate targets, develop biomarkers and perform translational studies.
Expertise Areas
- Mitochondrial-targeted drug discovery
- Neurodegenerative disease therapeutics (Parkinson's, ALS/MND)
- Small-molecule medicinal chemistry and lead optimisation
- Preclinical candidate selection and IND-enabling development
Key Technologies
- Phenotypic screening in isolated mitochondria
- Chemoproteomics for target ID
- Small-molecule medicinal chemistry
- Lead optimisation and ADME/PK profiling